Developing peptides that can effectively enter cells to target hard-to-reach disease areas
A data-driven approach towards generation of permeable peptide therapeutics
This study is working on developing new treatments made from tiny proteins that can get inside cells to target hard-to-reach areas, with the hope of finding better options for people with various diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oregon NIH-funded |
| Lab location | 1 site (Eugene, United States) |
| Project ID | NIH-11014626 on NIH RePORTER |
What this research studies
This research focuses on creating peptide-based therapeutics that can penetrate cell membranes to access previously undruggable targets inside cells. By utilizing advanced computational techniques and high-throughput screening methods, the project aims to identify and optimize peptides that can effectively bind to these challenging targets. The interdisciplinary approach combines machine learning and experimental data to enhance the development of permeable peptide therapeutics, potentially leading to new treatment options for various diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diseases that involve undruggable targets, particularly those that reside within cells.
Not a fit: Patients with conditions that are already effectively treated by existing therapies or those without undruggable targets may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies for diseases that currently have limited treatment options due to inaccessible targets.
How similar studies have performed: While the approach of using peptides as therapeutics is established, the specific methodology of targeting undruggable areas using advanced computational techniques is relatively novel and has not been extensively tested.
Where this research is happening
Eugene, United States
- University of Oregon — Eugene, United States (Active)
Researchers
- Principal investigator: Hosseinzadeh, Parisa — University of Oregon
- Study coordinator: Hosseinzadeh, Parisa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.